Sibel Blau
University of Washington Tacoma(US)
Publications by Year
Research Areas
Advanced Breast Cancer Therapies, Cancer Genomics and Diagnostics, HER2/EGFR in Cancer Research, Cancer Treatment and Pharmacology, COVID-19 and healthcare impacts
Most-Cited Works
- → Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer(2016)1,956 cited
- → Analytical and Clinical Validation of a Digital Sequencing Panel for Quantitative, Highly Accurate Evaluation of Cell-Free Circulating Tumor DNA(2015)710 cited
- → Ipatasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (LOTUS): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial(2017)466 cited
- → Buparlisib plus fulvestrant in postmenopausal women with hormone-receptor-positive, HER2-negative, advanced breast cancer progressing on or after mTOR inhibition (BELLE-3): a randomised, double-blind, placebo-controlled, phase 3 trial(2017)379 cited
- → Comparison of 2 Commercially Available Next-Generation Sequencing Platforms in Oncology(2016)169 cited
- → High-recovery visual identification and single-cell retrieval of circulating tumor cells for genomic analysis using a dual-technology platform integrated with automated immunofluorescence staining(2015)153 cited
- → Telehealth in Oncology: ASCO Standards and Practice Recommendations(2021)139 cited
- → Phase I/II Trial of Exemestane, Ribociclib, and Everolimus in Women with HR+/HER2− Advanced Breast Cancer after Progression on CDK4/6 Inhibitors (TRINITI-1)(2021)111 cited
- → Everolimus Plus Exemestane vs Everolimus or Capecitabine Monotherapy for Estrogen Receptor–Positive, HER2-Negative Advanced Breast Cancer(2018)109 cited
- → COVID-19 vaccination and breakthrough infections in patients with cancer(2021)98 cited